Nature Communications (Jan 2022)
A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19
- Yogiraj Ray,
- Shekhar Ranjan Paul,
- Purbita Bandopadhyay,
- Ranit D’Rozario,
- Jafar Sarif,
- Deblina Raychaudhuri,
- Debaleena Bhowmik,
- Abhishake Lahiri,
- Janani Srinivasa Vasudevan,
- Ranjeet Maurya,
- Akshay Kanakan,
- Sachin Sharma,
- Manish Kumar,
- Praveen Singh,
- Rammohan Roy,
- Kausik Chaudhury,
- Rajsekhar Maiti,
- Saugata Bagchi,
- Ayan Maiti,
- Md. Masoom Perwez,
- Abhinandan Mondal,
- Avinash Tewari,
- Samik Mandal,
- Arpan Roy,
- Moumita Saha,
- Durba Biswas,
- Chikam Maiti,
- Ritwik Bhaduri,
- Sayantan Chakraborty,
- Biswanath Sharma Sarkar,
- Anima Haldar,
- Bibhuti Saha,
- Shantanu Sengupta,
- Rajesh Pandey,
- Shilpak Chatterjee,
- Prasun Bhattacharya,
- Sandip Paul,
- Dipyaman Ganguly
Affiliations
- Yogiraj Ray
- Infectious Disease & Beleghata General Hospital
- Shekhar Ranjan Paul
- Infectious Disease & Beleghata General Hospital
- Purbita Bandopadhyay
- IICB-Translational Research Unit of Excellence, CSIR-Indian Institute of Chemical Biology
- Ranit D’Rozario
- IICB-Translational Research Unit of Excellence, CSIR-Indian Institute of Chemical Biology
- Jafar Sarif
- IICB-Translational Research Unit of Excellence, CSIR-Indian Institute of Chemical Biology
- Deblina Raychaudhuri
- IICB-Translational Research Unit of Excellence, CSIR-Indian Institute of Chemical Biology
- Debaleena Bhowmik
- Academy of Scientific and Innovative Research
- Abhishake Lahiri
- Academy of Scientific and Innovative Research
- Janani Srinivasa Vasudevan
- CSIR-Institute of Genomics and Integrative Biology
- Ranjeet Maurya
- CSIR-Institute of Genomics and Integrative Biology
- Akshay Kanakan
- CSIR-Institute of Genomics and Integrative Biology
- Sachin Sharma
- CSIR-Institute of Genomics and Integrative Biology
- Manish Kumar
- CSIR-Institute of Genomics and Integrative Biology
- Praveen Singh
- CSIR-Institute of Genomics and Integrative Biology
- Rammohan Roy
- Infectious Disease & Beleghata General Hospital
- Kausik Chaudhury
- Infectious Disease & Beleghata General Hospital
- Rajsekhar Maiti
- Infectious Disease & Beleghata General Hospital
- Saugata Bagchi
- Infectious Disease & Beleghata General Hospital
- Ayan Maiti
- Infectious Disease & Beleghata General Hospital
- Md. Masoom Perwez
- Infectious Disease & Beleghata General Hospital
- Abhinandan Mondal
- Infectious Disease & Beleghata General Hospital
- Avinash Tewari
- Infectious Disease & Beleghata General Hospital
- Samik Mandal
- Infectious Disease & Beleghata General Hospital
- Arpan Roy
- Infectious Disease & Beleghata General Hospital
- Moumita Saha
- Infectious Disease & Beleghata General Hospital
- Durba Biswas
- Department of Immunohematology & Blood Transfusion, Medical College
- Chikam Maiti
- Department of Immunohematology & Blood Transfusion, Medical College
- Ritwik Bhaduri
- Indian Statistical Institute
- Sayantan Chakraborty
- Department of Critical Care Medicine, Tata Medical Center
- Biswanath Sharma Sarkar
- Infectious Disease & Beleghata General Hospital
- Anima Haldar
- Infectious Disease & Beleghata General Hospital
- Bibhuti Saha
- Department of Tropical Medicine, School of Tropical Medicine
- Shantanu Sengupta
- Academy of Scientific and Innovative Research
- Rajesh Pandey
- Academy of Scientific and Innovative Research
- Shilpak Chatterjee
- IICB-Translational Research Unit of Excellence, CSIR-Indian Institute of Chemical Biology
- Prasun Bhattacharya
- Department of Immunohematology & Blood Transfusion, Medical College
- Sandip Paul
- Division of Structural Biology & Bioinformatics, CSIR-Indian Institute of Chemical Biology
- Dipyaman Ganguly
- IICB-Translational Research Unit of Excellence, CSIR-Indian Institute of Chemical Biology
- DOI
- https://doi.org/10.1038/s41467-022-28064-7
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 9
Abstract
Convalescent plasma therapy (CPT) is used to treat patients with Covid-19, but evidence for clinical benefit from clinical trials is divergent. Here the authors report in that CPT treatment does not affect mortality in patients with severe Covid-19 in phase 2 single center open label randomised controlled trial.
